Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028?
RegulierungOne-OffTechnikHealth & MedicineEquities1JManifold MarketsKein KYCVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle Community-PrognoseJa 70.2%
Prognostiker
4
Fragetyp
binary
Methodik
Play-money forecasting platform
Quellentyp
Prognose
Marktdaten
Aktualisiert vor 2 Stunden
Veraltet6. Aug. 26, 04:06 UTC31. Dez. 27, 23:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
Will Gustavo Petro face a criminal trial before January 1, 2027?
Manifold MarketsWill the VLA15 Lyme Disease vaccine "pass" its phase 3 human trial?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill Anthropic’s valuation hit __ by September 30?
PolymarketWill OpenAI's valuation hit __ by September 30?
PolymarketAnthropic’s valuation end of October 2026?
PolymarketRegeln
Will BGE-102 significantly reduce hsCRP in BioAge's Phase 2 QUELL-CV trial?
- BGE-102 is a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor discovered by BioAge Labs, Inc. (Nasdaq: BIOA).
- NLRP3 drives age-related chronic inflammation implicated in cardiovascular disease, metabolic disorders, and neurodegenerative conditions; BioAge has said its discovery platform nominated NLRP3 from analysis of human aging cohorts in which lower NLRP3 activity tracked with greater longevity (Aug 15, 2025).
- The company has also stated that its compounds engage a binding site and mechanism distinct from other NLRP3 inhibitors in development, with a composition-of-matter patent covering that site issued in January 2026 (Jan 12, 2026).
- Cardiovascular risk reduction is the lead indication.
- This market concerns the QUELL-CV primary endpoint only.
Offene Märkte
RegulationPOLYMARKETClarity Act (H.R.3633) signed into law in 2026?
- No+2.0pt86%
- Yes-2.0pt14%
- Gesamtvolumen
- 12,4 Mio. €
- 24h-Volumen
- 182.343,6 €
POLYMARKETAnthropic IPO by which date?
- December 31,-1.0pt90%
- December 15,+3.5pt90%
- November 30,85%
+7 weitere Ergebnisse
- Gesamtvolumen
KALSHIWill the Clarity Act become law?
- Before Jan 1, 2028-14.0pt40%
- Before Jul 1, 2027-5.0pt37%
- Before Oct 1, 2027-16.0pt33%
+7 weitere Ergebnisse
KALSHIWhen will Tesla and SpaceX merge?
- Before 2028+3.0pt67%
- Before May 1, 2027-1.0pt49%
- Before Apr 1, 2027-7.0pt43%
+8 weitere Ergebnisse
KALSHIWhen will Anthropic officially announce an IPO?
- Before Apr 1, 2027+5.0pt97%
- Before Jan 1, 202795%
- Before Mar 1, 2027-1.0pt94%
+9 weitere Ergebnisse
- Gesamtvolumen
- 1,4 Mio. €
POLYMARKETWhat will OpenAI's IPO valuation be?
- $1.25T–$1.5T-0.1pt20.4%
- $1.75T–$2.0T19.4%
- $1.5T–$1.75T+0.1pt18.4%
+5 weitere Ergebnisse
- Conference to Win the National Championship
- Will California authorize an alternative wage or other qualifying relief from goat-herder wage and overtime obligations before Oct 1, 2026?
- Which companies will officially announce an IPO this year?
- Discord IPO Closing Market Cap
- When will the Senate vote on the Clarity Act?
- SpaceX' Market Cap end of October 2026?
- Which Senators will vote for the Clarity Act?
- Space Exploration Technologies' Market Cap end of September 2026?
- Will Delaware raise its corporate franchise tax?
- Will marijuana be rescheduled?
Häufige Fragen
- Wie stehen die aktuellen Quoten für Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028??
- Manifold Markets bewertet Yes mit 70% (Stand: 8. September 2026).
- Wann wird Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? entschieden?
- Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? soll am 31. Dezember 2027 entschieden werden.
- Wie wird Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? abgerechnet?
- Manifold Markets rechnet diesen Markt wie folgt ab: Will BGE-102 significantly reduce hsCRP in BioAge's Phase 2 QUELL-CV trial?